U.S. drugmaker Pfizer Inc. (PFE) and BioNTech SE (BNTX) got the green light from German regulators to conduct the first in-human clinical trial in Germany of a potential coronavirus vaccine.Pfizer and BioNTech said they expected shortly to get regulatory approval to also start clinical trials in the U.S. Pfizer shares rose as much as 10% in early morning trading and were priced at $36.38 around midday. BioNtech stock surged 14% to $48.35.The Phase 1/2 trial comprises 4 vaccine candidates. The trial will include about 200 healthy individuals between the ages of 18 to 55 and aims to test the safety …read more
Source:: Yahoo Finance
